Skip to Main Content

Try STAT+ TODAY

cancer

Most Read

Biotech Adam Feuerstein

Gilead drug prolongs survival of women with common form of breast cancer

Biotech Matthew Herper

Relay Therapeutics drug shows promise in early trial

Biotech Damian Garde

Roche pays $250 million to acquire Good Therapeutics and its preclinical cancer therapy

First Opinion H. Gilbert Welch

Congress should not compel Medicare to pay for liquid biopsies

Matt's Take Matthew Herper

Why Illumina has a merger mess of its own making

First Opinion S. Monica Soni

People with terminal cancer need to know they are dying. Doctors shouldn’t withhold that information

Business Jonathan Wosen

Illumina wins case against FTC in bid to hold onto early cancer detection company Grail

First Opinion William G. Woods

As a pediatric cancer researcher, I admired the FDA. Then I got ALS

All Coverage

Biotech Allison DeAngelis

Medical pioneers team up to launch new cell therapy biotech

Biotech Adam Feuerstein

Data likely support approval of Amgen’s KRAS-targeted drug, but still come with disappointments

advertisement

Politics Sarah Owermohle

Biden appoints former government scientist as first leader of ARPA-H

Biotech Jason Mast

Cancer treatment devised in the 1980s has proven effective (again). Will it finally get approval?

First Opinion Michael B. Farber and Anand Shah

The FDA is at a crossroads for reducing tobacco-related disease and death

Health Angus Chen

Despite overall decline, late-stage cervical cancer cases are rising

Biotech Angus Chen

Virtual Event – Biomarkers: The Foundation of Personalized Oncology

On Target Angus Chen

Frustrated with nature’s biomarkers for cancer, biologists try making their own

Matt's Take Matthew Herper

The Senate’s drug pricing bill is an inevitable solution. It will still have plenty of unintended consequences

First Opinion Maimah Karmo

Triple-negative breast cancer highlights the need to act against health inequities

Biotech Adam Feuerstein

Serious liver side effects detour Amgen’s effort to expand use of its KRAS-blocking lung cancer drug

Pharmalot Ed Silverman

Civica Rx begins selling its first outpatient generic drug as it tries to overhaul the pharmaceutical supply chain

Heavyweights Angus Chen

The trust-builder: a cancer center director’s try-it-all strategy for breaking the barriers between research and Black patients

Biotech Allison DeAngelis

Alexis Borisy, biotech’s ‘man of many hats,’ dons another

Biotech Allison DeAngelis

American Cancer Society’s VC arm partners with Third Rock on oncology companies

Health Bob Herman

Collateral damage of the Fed’s interest rate hikes: People who put medical bills on credit cards

Exclusive Lev Facher

Biden picks renowned cancer surgeon Monica Bertagnolli as NCI chief

Biotech Jonathan Wosen

This biotech is betting dietary changes can reshape cancer care. Even if it works, can Faeth make a profit?

Pharmalot Ed Silverman

A Supreme Court review of a contentious patent issue would change the way pharma claims discoveries

Health Ryan Cross — The Boston Globe

George Church startup Manifold Bio raises $40M for ‘protein barcoding’ technology to improve drug testing

Biotech Adam Feuerstein

The biotech scorecard for the third quarter: 18 stock-moving events to watch

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Medical privacy post-Roe, fixing clinical trials, & the next Covid vaccines

Special Report Angus Chen

This clinical trial wanted to end breast cancer disparities. But first it needed to enroll Black women

First Opinion T. Salewa Oseni

Why I ask my patients about their faith or religion

Pharmalot Ed Silverman

Quantity over quality: FDA approved more cancer drugs than EMA, but they may not have always benefited patients